Author:
Pham M. N.,Apolo A. B.,De Santis M.,Galsky M. D.,Leibovich B. C.,Pisters L. L.,Siefker-Radtke A. O.,Sonpavde G.,Steinberg G. D.,Sternberg C. N.,Tagawa S. T.,Weizer A. Z.,Woods M. E.,Milowsky M. I.
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Committee 6, Milowsky MI, De Santis M, Apolo AB, Galsky MD, Leibovich BC, Siefker-Radke AO, Sonpavde G, Steinberg GD, Sternberg CN, Tagawa ST, Weizer AZ, Woods ME (2014) Treatment of Metastatic Cancer. In: Shariat SF, Matin S, Stenzl A (eds) Upper Tract Urothelial Carcinoma. Société Internationale d’Urologie, Montréal, pp 263–283
2. Galsky MD, Hahn NM, Rosenberg J et al (2011) A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 12:211–214. doi: 10.1016/S1470-2045(10)70275-8
3. Sternberg CN, Yagoda A, Scher HI et al (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64:2448–2458
4. Loehrer PJ, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066–1073
5. Sternberg CN, de Mulder PHM, Schornagel JH et al (2001) Randomized phase III trial of high–dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol 19:2638–2646
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献